Company* |
Product |
Description |
Indication |
Status (Date) |
| ||||
AUTOIMMUNE | ||||
Cambridge Antibody Technology Group plc (UK; CATG; LSE:CAT) and Abbott Laboratories |
Humira (FDA-approved) antagonist |
Adalimumab; human monoclonal antibody; tumor necrosis factor alpha |
Adult rheumatoid arthritis |
European Medicines Evaluation Agency granted a positive opinion on Humira (5/22) |
|
||||
Centocor Inc. (unit of Johnson & Johnson) and Schering- Plough Corp. |
Remicade (FDA-approved) |
Infliximab; monoclonal antibody that specifically targets and irreversibly binds to TNF-alpha |
Ankylosing spondylitis and Crohn's disease |
Companies received European Union approval of Remicade (5/21) |
|
||||
CANCER | ||||
Altachem Pharma Ltd. (Canada; VSE:AAF) |
ACP-HIP |
A natural compound throught to be active against the causative viral agent of Kaposi's sarcoma |
Kaposi's sarcoma |
Company will begin a Phase I trial in Canada (5/13) |
|
|
|||
Oncolytics Biotech Inc. (Canada; TSE:ONC) |
Reolysin |
A human, reovirus-based product |
Recurrent malignant glioma |
Enrollment resumed in a Phase I trial in Canada (5/7) |
|
||||
Viventia Biotech Inc. (Canada; TSE:VBI) |
VB4-845 |
Armed Antibodies targeted therapeutic candidate, designed to deliver potent cytotoxic agents directly to tumors |
Head and neck cancer |
Company will begin a Phase I trial in Switzerland (5/6) |
|
|
|||
INFECTION | ||||
Corixa Corp. (CRXA) and GlaxoSmithKline plc (UK) |
Fendrix |
Vaccine that includes the GSK Bio Hepatitis B antigen with the addition of Corixa's MPL adjuvant |
Hepatitis B |
GlaxoSmithKline filed for European approval (5/13) |
|
||||
Gilead Sciences Inc. (GILD) |
Viread (FDA-approved) |
Tenofovir disoproxil fumarate |
HIV |
European regulatory authorities expanded the indication to include Viread's use in antiretroviral-naive HIV infected patients (5/27) |
|
||||
Immtech International Inc. (IMMT) |
DB289 compound |
Oral anti-infective; dicationic pharmaceutical |
Malaria |
Company is beginning a Phase IIa trial in Thailand (5/15) |
|
||||
Salix Pharmaceuticals Ltd. (SLXP) |
Rifaximin |
Gastrointestinal tractrestricted antibiotic |
Travelers' diarrhea |
Company completed enrollment in a Phase III trial with 400 adults in Mexico, Guatemala, India and Peru (5/14) |
|
||||
Trimeris Inc. (TRMS) and Hoffmann- La Roche Inc. |
Fuzeon (FDA-approved) |
Enfuvirtide; fusion inhibitor |
HIV |
European Commission approved Fuzeon (5/28) |
|
||||
Vicuron |
Dalbavancin |
A next-generation glycopeptide agent that belongs to the same class as vancomycin |
Deep skin and soft tissue infections |
Phase II data showed a once-weekly dose of dalbavancin was effective and well tolerated over two weeks (5/12) |
|
||||
MISCELLANEOUS | ||||
Novogen Ltd. |
Glucoprime |
A skin-ulcer repair compound |
Skin ulcer |
Company began a Phase II trial at three sites in Australia (5/8) |
|
||||
Sangart Inc.* |
Hemospan |
Hemoglobin-based red blood cell substitute |
Patients undergoing elective orthopedic surgeries |
Company began a Phase Ib/II trial of Hemospan (5/8) |
| ||||
Notes: | ||||
* Privately held | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
LSE = London Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. |